Targets › SMARCA2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.
ATPase involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner. (UniProt, P51531)
Open in Phaseline: the race on SMARCA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Plexium | PLX-61639 SMARCA2 degrader | SMARCA2 | Phase 1 | Esophageal Squamous Cell Carcinoma | Dec 2029 |
Esophageal Squamous Cell Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.